Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elesclomol Sodium + Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
NCT00888615Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Dec 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elesclomol in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Primary endpoints: Proportion of Participants With Objective Response up to 5 years, Duration of Objective Response up to 5 years and 2 more. Started Dec 2010; status: completed.
02
Drugs
elesclomol
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00888615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888615.